Endothelial Cells

Overview

Functional vascular endothelial cells differentiated from UCT-WJ-MSCs; producing nitric oxide, VEGF, and angiopoietins for blood vessel formation, vascular repair, and blood pressure regulation

Related: Stem Cells Overview • Endothelial Exosomes

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Clinical Overview

Endothelial dysfunction is a unifying pathological mechanism in cardiovascular disease, diabetes complications, chronic wounds, erectile dysfunction, and ischemic stroke. Akira Endothelial Cells restore vascular homeostasis through three complementary mechanisms: direct incorporation into new blood vessels (vasculogenesis), paracrine stimulation of angiogenesis in ischemic tissue, and restoration of endothelial-derived vasoprotective molecules (NO, prostacyclin) that regulate vascular tone and prevent thrombosis. UCT-WJ-MSC-derived endothelial cells form more patent tube networks than adult endothelial sources in Matrigel assays — reflecting the developmental potency advantage of perinatal origin.^[1] Their delivery (IV, intra-arterial, or direct injection) has demonstrated efficacy in restoring blood flow in peripheral arterial disease models and reducing hypertension-induced vascular remodeling.

Mechanism of Action

Vasculogenesis: CD31+/VE-Cadherin+ endothelial cells directly incorporate into nascent capillaries in ischemic tissue, establishing new microvascular networks that restore perfusion to hypoxic zones, consistent with the spatial and temporal dynamics of endothelial network formation described in the broader vascular biology literature.^[2]

NO Synthesis & Vasoregulation: eNOS (endothelial nitric oxide synthase) generates NO from L-arginine, causing vascular smooth muscle relaxation (vasodilation), inhibition of platelet aggregation, and anti-inflammatory effects on vessel walls. This directly addresses hypertension, endothelial dysfunction, and atherosclerosis risk.

Angiogenic Paracrine Signaling: VEGF-A, Ang-1, EGF, HGF, and PDGF secretion activates endothelial proliferation, migration, and lumen formation in surrounding pericyte-coated vessels — amplifying neovascularization beyond transplanted cell count, guided by growth-factor gradients^[3] through the sprouting-angiogenesis process by which new capillaries branch from existing vessels.^[4]

Barrier Restoration: Akira Endothelial Cells upregulate tight junction proteins (claudin-5, occludin, ZO-1) to restore vascular barrier integrity after ischemia-reperfusion injury, reducing tissue edema and inflammatory leukocyte infiltration.

Anti-Thrombotic Properties: Prostacyclin (PGI2) and thrombomodulin expression creates an anti-coagulant surface preventing microvascular thrombosis in ischemic conditions.

Key Biomarkers & Molecular Cargo

Potential Applications

• Peripheral Artery Disease (PAD) — therapeutic angiogenesis, critical limb ischemia
• Ischemic Stroke — cerebrovascular repair, BBB restoration
• Hypertension — eNOS restoration, vascular smooth muscle relaxation
• Erectile Dysfunction — penile microvascular regeneration, NO pathway restoration
• Chronic Wound Healing (diabetic ulcers, venous ulcers) — neovascularization of wound bed
• Microcirculation Disorders — Raynaud's phenomenon, small vessel disease
• Diabetic Angiopathy — retinal, renal, and peripheral vascular bed repair
• Post-MI Revascularization — coronary microvascular repair adjunct

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

Preclinical hindlimb ischemia models (PAD simulation) and hypertensive rat (SHR) models of MSC-derived endothelial cell administration report improved limb salvage, perfusion, and capillary density in the ischemia models, and reduced systolic blood pressure with restored endothelium-dependent vasodilation and vascular remodeling reversal in the hypertensive models — directionally consistent with the mechanisms above, though this specific preclinical evidence base is not yet tied to a single verifiable published source and should be treated as supportive rather than quantitatively definitive. Therapeutic angiogenesis has independently demonstrated safety and efficacy in critical limb ischemia patients, supporting the underlying clinical rationale for this approach.^[5]

In a diabetic (STZ) rat model of erectile dysfunction, corpus cavernosal delivery of eNOS-expressing endothelial cells restored the intracavernosal pressure/mean arterial pressure (ICP/MAP) ratio to roughly 65% of normal (versus ~20% in untreated diabetic controls), normalized NOS expression and NO levels, and restored smooth muscle relaxation — the biological basis for the Akira Endothelial Cell and Endothelial Exosome products in the P-Shot MAX formulation.^[6]

A 2023 review of MSC-derived exosomes containing endothelial cargo (VEGF, miR-126, eNOS, angiopoietins) confirmed efficacy in peripheral artery disease, ischemic stroke, and wound healing preclinical models — mechanistically validating the Akira Endothelial Exosome product.^[7]